Fibrilization in mouse senile amyloidosis is fibril conformation- dependent

Laboratory Investigation

Volumn 78, Issue 12, 1998, Pages 1535-1542

  Higuchi, Keiichi ^a   Kogishi, Kumiko ^b   Wang, Jing ^b   Chen, Xia ^b   Chiba, Takuya ^b   Matsushita, Takatoshi ^b   Hoshii, Yoshinobu ^c   Kawano, Hiroo ^c   Ishihara, Tokuhiro ^c   Yokota, Tadaaki ^a   Hosokawa, Masanori ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; HIGH DENSITY LIPOPROTEIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; HISTOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DETERMINATION; TISSUE DISTRIBUTION;

AGING; AMYLOID; AMYLOIDOSIS; ANIMALS; APOLIPOPROTEIN A-II; LIPOPROTEINS, HDL; LIVER; MICE; MICE, MUTANT STRAINS; NEUROFIBRILS; SPLEEN;

EID: 0032422306     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Bessen RA, Kocisko DA, Raymond GJ, Nandan S, Lansbury PT, and Caughey B (1995). Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 375:698-700.
2. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CC, and Pepys MB (1997). Instability, unfolding and aggregation of human lysoyme variants underlying amyloid fibrillogenesis. Nature 385:787-793.
3. Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, and Pepys MB (1997). Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3:855-859.
4. Bruce M, Chree A, McConnell I, Foster J, Pearson G, and Fraser H (1994). Transmission of bovine spongiform encephalopathy and scrapie to mice: Strain variation and the species barrier. Philos Trans R Soc Lond Biol 343:405-411.
5. Cohen AS and Jones LA (1993). Advances in amyloidosis. Curr Opin Rheumatol 5:62-76.
6. Collinge J, Sidle KC, Meads J, Ironside J, and Hill AF (1996). Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 383:685-690.
7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, and Pericak-Vance MA (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families [see comments]. Science 261:921-923.
8. Davis BJ (1964). Disc electrophoresis-II. Method and application to human serum protein. Ann NY Acad Sci 121:404-427.
9. De-Coen J, Deboeck M, Delcroix C, Lontie JF, and Malmendier CL (1988). Proposed folding pattern for apolipoprotein A-II based on a structural analogy with uteroglobin. Proc Natl Acad Sci USA 85:5669-5672.
10. Evans KC, Berger EP, Cho CG, Weisgraber KH, and Lansbury P Jr (1995). Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA 92:763-767.
11. Ganowiak K, Hultman P, Engstrom U, Gustavsson A, and Westermark P (1994). Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. Biochem Biophys Res Commun 199: 306-312.
12. Glenner GG (1980). Amyloid deposits and amyloidosis: The §-fibrilloses. N Engl J Med 302:1283-1292.
13. Higuchi K (1997). Genetic characterization of senescence-accelerated mouse (SAM). Exp Gerontol 32:129-138.
14. Higuchi K, Kitado H, Kitagawa K, Kogishi K, Naiki H, and Takeda T (1993). Development of congenic strains of mice carrying amyloidogenic apolipoprotein A-II (Apoa2c). Apoa2c reduces the plasma level and the size of high density lipoprotein. FEBS Lett 317:207-210.
15. Higuchi K, Kitagawa K, Naiki H, Hanada K, Hosokawa M, and Takeda T (1991a). Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. Biochem J 279:427-433.
16. Higuchi K, Kogishi K, Wang J, Xia C, Chiba T, Matsushita T, and Hosokawa M (1997). Accumulation of pro-apolipoprotein A-II in mouse senile amyloid fibrils. Biochem J 325:653-659.
17. Higuchi K, Matsumura A, Honma A, Takeshita S, Hashimoto K, Hosokawa M, Yasuhira K, and Takeda T (1983). Systemic senile amyloid in senescence-accelerated mice: A unique fibril protein demonstrated in tissues from various organs by the unlabeled immunoperoxidase method. Lab Invest 48: 231-240.
18. Higuchi K, Naiki H, Kitagawa K, Hosokawa M, and Takeda T (1991b). Mouse senile amyloidosis. ASSAM amyloidosis in mice presents universally as a systemic age-associated amyloidosis. Virchows Arch B Cell Pathol Incl Mol Pathol 60:231-238.
19. Higuchi K, Naiki H, Kitagawa K, Kitado H, Kogishi K, Matsushita T, and Takeda T (1995). The apoA-II gene and development of amyloidosis and senescence in a congenic strains of mice carrying amyloidogenic apoA-II. Lab Invest 72:75-82.
20. Higuchi K, Wang J, Kitagawa K, Matsushita T, Kogishi K, Naiki H, Kitado H, and Hosokawa M (1996). Accelerated senile amyloidosis induced by amyloidogenic apoA-II gene shortens the life span of mice but does not accelerate the rate of senescence. J Gerontol 51A:B295-B302.
21. Higuchi K, Yonezu T, Kogishi K, Matsumura A, Takeshita S, Higuchi K, Kohno A, Matsushita M, Hosokawa M, and Takeda T (1986). Purification and characterization of a senile amyloid-related antigenic substance (apoSASSAM) from mouse serum. apoSASSAM is an apoA-II apolipoprotein of mouse high density lipoproteins. J Biol Chem 261:12834-12840.
22. HogenEsch H, Niewold TA, Higuchi K, Tooten PC, Gruys E, and Radl J (1993). Gastrointestinal AAPOAII and systemic AA-amyloidosis in aged C57BL/Ka mice: Amyloid-type dependent effect of long-term immunosuppressive treatment. Virchows Arch B Cell Pathol Incl Mol Pathol 64:37-43.
23. Horwich AL and Weissman JS (1997). Deadly conformations-protein misfolding in prion disease. Cell 89:499-510.
24. Jarrett JT and Lansbury PJ (1993). Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-1058.
25. Kelly JW (1998a). The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8:101-106.
26. Kelly JW (1998b). The environmental dependency of protein folding best explains prion and amyloid diseases [comment]. Proc Natl Acad Sci USA 95:930-932.
27. Kelly JW and Lansbury PTJ (1994). A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid 3:186-205.
28. Kisilevsky R, Gruys E, and Shirahama T (1995). Does amyloid enhancing factor (AEF) exist? Is AEF a single biological entity? Amyloid 2:126-127.
29. Kohno A, Yonezu T, Matsushita M, Irino M, Higuchi K, Higuchi K, Takeshita S, Hosokawa M, and Takeda T (1985). Chronic food restriction modulates the advance of senescence in the senescence accelerated mouse (SAM). J Nutr 115:1259-1266.
30. McKinley MP, Meyer RK, Kenaga L, Rahbar F, Cotter R, Serban A, and Prusiner SB (1991). Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J Virol 65:1340-1351.
31. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, and Kelly JW (1996). Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 93: 15051-15056.
32. Moore RC, Hope J, McBride PA, McConnel I, Selfridge J, Melton DW, and Manson JC (1998). Mice with gene targetted prion protein alteration show that Prnp, Sine and Prni are congruent. Nature Genet 18:118-125.
33. Naiki H and Nakakuki K (1996). First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro. Lab Invest 74:374-383.
34. Naiki H, Higuchi K, Hosokawa M, and Takeda T (1989). Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem 177:244-249.
35. Naiki H, Higuchi K, Nakakuki K, and Takeda T (1991). Kinetic analysis of amyloid fibril polymerization in vitro. Lab Invest 65:104-110.
36. Niewold TA, Hol PR, van-Andel AC, Lutz ET, and Gruys E (1987). Enhancement of amyloid induction by amyloid fibril fragments in hamster. Lab Invest 56:544-549.
37. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, and Prusiner SB (1993). Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 90:10962-10966.
38. Pras M, Zucker-Franklin D, Rimon A, and Franklin EC (1969). Physical, chemical, and ultrastructural studies of water-soluble human amyloid fibrils. J Exp Med 130:777-791.
39. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinski RJ, Wasco W, Da Silva HAR, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, and St. George-Hyslop PH (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754-760.
40. Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, Mastrianni J, Lugaresi E, Gambetti P, and Prusiner SB (1996). Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagation prion diversity. Science 274:2079-2082.
41. Umezawa M, Hosokawa M, Kohno A, Ishikawa S, Kitagawa K, and Takeda T (1993). Dietary soybean protein compared with casein retards senescence in the senescence accelerated mouse. J Nutr 123:1905-1912.
42. Wang J, Kitagawa K, Kitado H, Kogishi K, Matsushita T, Hosokawa M, and Higuchi K (1997). Regulation of the metabolism of plasma lipoproteins by apolipoprotein A-II. Biochim Biophys Acta 1345:248-258.
43. Wille H, Zhang GF, Baldwin MA, Cohen FE, and Prusiner SB (1996). Separation of scrapie prion infectivity from PrP amyloid polymers. J Mol Biol 259:608-621.
44. Yokota T, Ishihara T, Kawano H, Takahashi M, Yamashita Y, Gondo T, Fujinaga Y, and Uchino F (1989). Immunocytochemical evidence of amyloid-enhancing factor (AEF) in polymorphonuclear leukocytes. Acta Pathol Jpn 39:349-355.
45. Yokota T, Takahashi M, Ishihara T, Yamashita Y, Gondo T, Kawamura S, Hoshii Y, Koga M, Iwata T, and Uchino F (1991). Amyloid enhancing factor (AEF): Isolation and biochemical and pathological characteristics. Acta Pathol Jpn 41:798-805.
46. Yonezu T, Higuchi K, Tsunasawa S, Takagi S, Sakiyama F, and Takeda T (1986). High homology is present in the primary structures between murine senile amyloid protein (ASSAM) and human apolipoprotein A-II. FEBS Lett 203:149-152.